Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight [Yahoo! Finance]
Immunovant (IMVT) had its "neutral" rating reaffirmed by The Goldman Sachs Group, Inc..
Immunovant (IMVT) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM [Yahoo! Finance]
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]